Adapting to darkness

Article

Scientists studying a neural retina in a salamander have found Müller cells in the promoted cone-specific pigment regeneration and dark adaptation that are independent of the pigment epithelium.

Scientists studying a neural retina in a salamander found Müller cells in the promoted cone-specific pigment regeneration and dark adaptation that are independent of the pigment epithelium.

Similar to glial cells in the brain Müller cells in the retina support and interact with photoreceptors. The researchers removed the pigment epithelium layer preventing the pigment molecules from recycling using a known pathway. They then exposed the retina to bright light then darkness and found that the cones continued to function, making it clear that a second pathway was being employed.

Their discovery will enhance our understanding of human diseases affecting the retina, including age-related macular degeneration (AMD). The researchers results are published in the March issue of Nature Neuroscience.

Principal investigator Vladimir J. Kefalov, PhD, assistant professor of ophthalmology and visual sciences at Washington University School of Medicine believes that there are major implications for AMD, where cone cells malfunction over time. This would take the form of targeting the pathway, revving up its activity and supplementing or rescuing the function of the cones.

Before that happens, he says it will be important to figure out exactly how the Müller cells are interacting with photoreceptors. Although these studies confirmed the existence of the second photoreceptor pathway, they didn't reveal how it works. Kefalov's laboratory has recently received a five-year, $1.9 million National Eye Institute grant to study how this newly identified visual pathway functions in the retina.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.